JP2013534410A - 悪性神経膠腫においてｄｏｗｎｒｅｇｕｌａｔｅｄｉｎｒｅｎａｌｃｅｌｌｃａｒｃｉｎｏｍａの発現を減少させる方法 - Google Patents

悪性神経膠腫においてｄｏｗｎｒｅｇｕｌａｔｅｄｉｎｒｅｎａｌｃｅｌｌｃａｒｃｉｎｏｍａの発現を減少させる方法 Download PDF

Info

Publication number
JP2013534410A
JP2013534410A JP2013510459A JP2013510459A JP2013534410A JP 2013534410 A JP2013534410 A JP 2013534410A JP 2013510459 A JP2013510459 A JP 2013510459A JP 2013510459 A JP2013510459 A JP 2013510459A JP 2013534410 A JP2013534410 A JP 2013534410A
Authority
JP
Japan
Prior art keywords
drr
cell
expression
glioma
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534410A5 (enExample
JP2013534410A6 (ja
Inventor
ケヴィン ペトレッカ
マサド ダムハ
グレン デリーヴィー
Original Assignee
ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マクギル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マクギル ユニバーシティ filed Critical ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マクギル ユニバーシティ
Publication of JP2013534410A publication Critical patent/JP2013534410A/ja
Publication of JP2013534410A6 publication Critical patent/JP2013534410A6/ja
Publication of JP2013534410A5 publication Critical patent/JP2013534410A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013510459A 2010-05-18 2011-05-18 悪性神経膠腫においてｄｏｗｎｒｅｇｕｌａｔｅｄｉｎｒｅｎａｌｃｅｌｌｃａｒｃｉｎｏｍａの発現を減少させる方法 Pending JP2013534410A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34575110P 2010-05-18 2010-05-18
US61/345,751 2010-05-18
PCT/CA2011/000591 WO2011143762A1 (en) 2010-05-18 2011-05-18 Method for reducing expression of downregulated iν renal cell carcinoma iν malignant gliomas

Publications (3)

Publication Number Publication Date
JP2013534410A true JP2013534410A (ja) 2013-09-05
JP2013534410A6 JP2013534410A6 (ja) 2013-11-21
JP2013534410A5 JP2013534410A5 (enExample) 2014-07-03

Family

ID=44991131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510459A Pending JP2013534410A (ja) 2010-05-18 2011-05-18 悪性神経膠腫においてｄｏｗｎｒｅｇｕｌａｔｅｄｉｎｒｅｎａｌｃｅｌｌｃａｒｃｉｎｏｍａの発現を減少させる方法

Country Status (7)

Country Link
US (2) US8765708B2 (enExample)
EP (1) EP2571989A4 (enExample)
JP (1) JP2013534410A (enExample)
CN (1) CN103370414A (enExample)
AU (1) AU2011256098A1 (enExample)
CA (1) CA2836315A1 (enExample)
WO (1) WO2011143762A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
RU2747822C2 (ru) * 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
WO2019154884A1 (en) * 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
US12104152B2 (en) 2018-03-19 2024-10-01 The Trustees Of The University Of Pennsylvania 2′F-ANA-LET7 mediated utrophin upregulation for DMD therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
US20070048738A1 (en) * 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
EP1737957A1 (en) * 2004-04-22 2007-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
EP1815021A2 (en) * 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
CN101474413A (zh) * 2009-02-10 2009-07-08 四川大学 Drr1基因在制备抗肿瘤药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEURO-ONCOLOGY, vol. 7, no. 3, JPN6015029513, 2005, pages 286 - 17, ISSN: 0003120293 *

Also Published As

Publication number Publication date
US9493772B2 (en) 2016-11-15
CA2836315A1 (en) 2011-11-24
US20130197057A1 (en) 2013-08-01
EP2571989A1 (en) 2013-03-27
CN103370414A (zh) 2013-10-23
WO2011143762A1 (en) 2011-11-24
US20140343124A1 (en) 2014-11-20
EP2571989A4 (en) 2014-08-13
AU2011256098A1 (en) 2013-01-10
US8765708B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
JP2017500026A (ja) 心筋細胞新生におけるｈｉｐｐｏ及びジストロフィン複合体シグナル伝達
WO2016057980A1 (en) Methods to eliminate cancer stem cells by targeting cd47
KR20120048613A (ko) Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
US12031135B2 (en) p63 inactivation for the treatment of heart failure
WO2022271818A1 (en) Antisense compounds and methods for targeting cug repeats
KR20190000385A (ko) 섬유증의 검출 및 치료
JP6895175B2 (ja) エクソソーム分泌阻害剤
EP2723350B1 (en) New uses of nanog inhibitors and related methods
CA2538208A1 (en) Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
US9493772B2 (en) Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
JP2013534410A6 (ja) 悪性神経膠腫においてｄｏｗｎ ｒｅｇｕｌａｔｅｄ ｉｎ ｒｅｎａｌ ｃｅｌｌ ｃａｒｃｉｎｏｍａの発現を減少させる方法
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
US20140128450A1 (en) Cancer Therapy
US11566247B2 (en) Modulation of alternative MDM2 splicing
US11981896B2 (en) p21 mRNA target areas for silencing
WO2013075233A1 (en) Method for treating brain cancer
Woll et al. Drugging pre-mRNA splicing
KR102563931B1 (ko) 스플라이스좀 관련 단백질인 IK의 용도로서 ATM 키나아제 pre-mRNA의 스플라이싱을 조절하는 방법
WO2025155251A1 (en) Methods of treating dystrophinopathies
JP2021153542A (ja) Ｃｂｆ１結合核酸分子およびその用途
Smith An Investigation into the Mechanism of Action of the SMN2 Bifunctional Oligonucleotide and its Application to Reverse the RON Δ165 Pro-Metastatic Splicing Event
US20080166349A1 (en) Method to Inhibit the Propagation of an Undesired Cell Population
JP2018172285A (ja) 細胞内の異常物質蓄積を伴う疾患の治療薬、バイオマーカー、診断薬、並びに、スクリーニング方法
MX2007004364A (es) E2-epf5, una proteina terapeutica novedosa y diana

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160316